Genetically engineered Bifidobacterium longum for tumor‐targeting enzyme‐prodrug therapy of autochthonous mammary tumors in rats
Open accessThe DOI matches its Crossref record.
Abstract
A fundamental obstacle in systemic therapy for cancer patients is the specific targeting of therapy directly to solid tumors. A strain of the domestic bacterium Bifidobacterium longum, which is non‐pathogenic and anaerobic, showed selective localization to and proliferation within solid tumors after systemic application. Here, we propose a novel approach to cancer gene therapy in which anaerobic and non‐pathogenic bacteria of the genus B. longum are used to achieve tumor‐specific gene delivery and enzyme‐prodrug therapy. We constructed a plasmid, pBLES100‐S‐eCD, which included eCD. Transfected B. longum produced CD in hypoxic tumors and achieved tumor site‐specific conversion of 5‐FC to 5‐FU. Furthermore, we demonstrated antitumor efficacy in rat bearing autochthonous mammary tumors injected with the transfected B. longum directly or intravenously. This method was confirmed to be effective for enzyme‐prodrug therapy not only by intratumoral injection but also by systemic administration. To estimate the toxicity of this bacterial vector, the systemic immunogenicity was evaluated by ASA reaction and the anaphylactic activity of IgG was evaluated by PCA reaction in guinea pigs. In the ASA reaction, no anaphylaxis symptoms were observed in any immunized guinea pigs injected with transfected B. longum. In the PCA reaction, B. longum/S‐eCD specific‐PCA‐induced antibody was not detected. Thus, we proposed that anaerobic bacteria of the genus B. longum were an attractive and safe tumor‐targeting vector and transfected B. longum was a potential anticancer agent that could effectively and specifically treat solid tumors. (Cancer Sci 2006; 97: 649–657)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bacteria-cancer interactions: bacteria-based cancer therapy
Duong, M. T.-Q., Qin, Y., You, S.-H., & Min, J.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0297-0 · Cited by 519
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138
Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum
Taniguchi, S., Shimatani, Y., & Fujimori, M. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3515-4_5 · Cited by 41
Self-citationShimizu, Y., Isoda, K., Taira, Y., Taira, I., Kondoh, M., & Ishida, I. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173596 · Cited by 32
Metadata
- Authors
- Sasaki, T., Fujimori, M., Hamaji, Y., Hama, Y., Ito, K., Amano, J., & Taniguchi, S.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2006-05-15
- Volume
- 97
- Issue
- 7
- Pages
- 649-657
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2074755058
- Cited by
- 127
- References
- 0
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetically engineered Bifidobacterium longum for tumor‐targeting enzyme‐prodrug therapy of autochthonous mammary tumors in rats. https://app.cochat.ai/papers/10.1111/j.1349-7006.2006.00221.x
- The paper
- Sasaki, T., Fujimori, M., Hamaji, Y., Hama, Y., Ito, K., Amano, J., & Taniguchi, S. (2006). Genetically engineered Bifidobacterium longum for tumor‐targeting enzyme‐prodrug therapy of autochthonous mammary tumors in rats. Cancer Science. https://doi.org/10.1111/j.1349-7006.2006.00221.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.